|
Dr. Turner joined NUCRYST in June 2006 as Vice President, Research where she led the company's pharmaceutical research exploring ways of expanding our pipeline of pharmaceutical products. In June 2007, Dr. Turner was appointed Vice President, Research and Development, responsible for guiding the research and development of the company's medical products pipeline. Her expanded role includes leading preclinical development and pharmaceutical services, while continuing to oversee analytical chemistry, microbiology and immunology research.
Prior to NUCRYST, Dr. Turner served as Vice President, Validation Biology at Biogen Idec Inc., where she directed research in immunology, neurobiology, fibrosis and oncology. Prior to this, she rose through positions of increasing responsibilities at Genetics Institute and its successor, Wyeth, to Vice President, Immunology and Hemostasis.
Dr. Turner earned a B.Sc. with honors at the University of Sussex, U.K. and an M.S. and Ph.D. in Biochemistry at Virginia Tech. In addition, she carried out post-doctoral research at Brandeis University and London University. She has published extensively in peer-reviewed journals, authored chapters in textbooks and presented research findings at symposia and professional meetings. | 